Acalabrutinib covalently binds BTK at the cysteine-481 residue and inhibits with greater in vivo potency and selectivity than ibrutinib [15] and also has demonstrated efficacy in early clinical trials involving relapsed and refractory CLL [16]. This evidence concerns the gene BTK and B-cell chronic lymphocytic leukemia.